Sreerama Shetty

This inventor holds 8 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: The University of Texas System, Rein Therapeutics, Inc.. Active years: 2014-2025.

USPTO Granted Patents = 8 (Patent Applications = 11)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 1.9

ph-index = 4

Forward Citations = 49(Granted Patents)

Company Filing History:

8 out of 5,630

The University of Texas System

patents

1 out of 3

Rein Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12280089 - Dry powder formulation of caveolin-1 peptides and methods of use thereof (2025-04-21),

2. 12173089 - Inhibition of pulmonary fibrosis with nutlin-3A and peptides (2024-12-24),

3. 12173061 - Compositions and methods for treatment of chronic lung diseases (2024-12-24),

4. 11780879 - Inhibition of pulmonary fibrosis with nutlin-3A and peptides (2023-10-10),

5. 11161875 - Inhibition of pulmonary fibrosis with nutlin-3a and peptides (2021-11-02),

6. 10377796 - Inhibition of pulmonary fibrosis with nutlin-3a and peptides (2019-08-13),

7. 9630990 - Inhibition of pulmonary fibrosis with nutlin-3A and peptides (2017-04-25),

8. 8697840 - Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis (2014-04-15),

Title: Sreerama Shetty: Innovator in Lung Disease Treatments

Introduction

Sreerama Shetty is a notable inventor based in Tyler, TX (US), recognized for his contributions to the field of medical science, particularly in the treatment of lung diseases. With a total of 8 patents, Shetty has made significant strides in developing innovative therapies aimed at improving patient outcomes.

Latest Patents

Among his latest patents, Shetty has developed a dry powder formulation of caveolin-1 peptides, which includes compositions comprising caveolin-1 (Cav-1) peptides. This invention provides methods for using Cav-1 peptides in the treatment of lung infections or acute and chronic lung injuries, particularly lung fibrosis. Another significant patent focuses on methods for treating chronic lung diseases, specifically idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia. This patent outlines various methods that involve administering biologically active fragments of multiple EGF-like-domains-9 (MEGF9), uncoordinated receptor 5A (UNC5A), and dolichyl-phosphate beta-glucosyltransferase (ALG5), among other combinations.

Career Highlights

Sreerama Shetty has worked with esteemed organizations such as the University of Texas System and Rein Therapeutics, Inc. His work in these institutions has allowed him to advance his research and contribute to the development of innovative medical solutions.

Collaborations

Throughout his career, Shetty has collaborated with notable colleagues, including Steven Idell and Dale Christensen. These partnerships have played a crucial role in enhancing the scope and impact of his research.

Conclusion

Sreerama Shetty's innovative work in the field of lung disease treatments showcases his dedication to improving healthcare through scientific advancements. His patents reflect a commitment to addressing critical health challenges, making him a significant figure in medical innovation.